Cargando…

P-042: POPULATION PHARMACOKINETICS AND PHARMACODYNAMICS ANALYSIS OF HYDROXYUREA, IN ADULT PATIENTS WITH SICKLE CELL DISEASE (SCD) RECEIVING BOTH TABLETS OR CAPSULES FORMULATIONS, AND EVALUATION OF DISEASE MARKERS

Detalles Bibliográficos
Autores principales:	P., BARTOLUCCI, S., LEZZAR, A., HABIBI, G., DE LUNA, A., JEBALI, S., MARTINO, C., NOIZAT, C., FAUROUX, F., GALACTÉROS
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Poster Presentations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429904/ http://dx.doi.org/10.1097/01.HS9.0000873064.94791.2e

Ejemplares similares

Biological parameters predictive of percent dense red blood cell decrease under hydroxyurea
por: Rakotoson, Marie Georgine, et al.
Publicado: (2015)

Population pharmacokinetics and pharmacodynamics of hydroxyurea in sickle cell anemia patients, a basis for optimizing the dosing regimen
por: Paule, Ines, et al.
Publicado: (2011)

Case Report of Myelodysplastic Syndrome in a Sickle-Cell Disease Patient Treated with Hydroxyurea and Literature Review
por: Flevari, Pagona, et al.
Publicado: (2022)

P-090: IS A DEDICATED MARKETING APPROVAL OF HYDROXYUREA IN SICKLE CELL DISEASE MAY INCREASE THE CLINICAL BENEFIT OF THE DRUG?
por: F., GALACTÉROS, et al.
Publicado: (2022)

P1438: L-GLUTAMINE: A NOVEL AND EFFECTIVE THERAPEUTIC TOOL FOR VOC REDUCTION IN SCD
por: Zaouali, Yosr, et al.
Publicado: (2023)

Drepadom - Establishment of Home Care Services and Hospitalizations for Sickle Cell Disease Patients As Standard Care Since the Covid-19 Pandemic
por: Pelinski, Yanís, et al.
Publicado: (2021)

Hydroxyurea Treatment for Sickle Cell Disease
por: Steinberg, Martin H.
Publicado: (2002)

The Effects of Treatment with Blood Transfusion, Iron Chelation and Hydroxyurea on Puberty, Growth and Spermatogenesis in Sickle Cell Disease (SCD): A short update
por: Soliman, Ashraf T, et al.
Publicado: (2021)

PB2505: THERAPEUTIC PHLEBOTOMY INSTANTLY AFFECTS BLOOD PARAMETERS AND VISCOCITY IN SICKLE CELL DISEASE PATIENTS
por: Jebali, Amna, et al.
Publicado: (2023)

Effective control of sickle cell disease with hydroxyurea therapy
por: Singh, Harminder, et al.
Publicado: (2010)

Evaluation of hydroxyurea genotoxicity in patients with sickle cell disease
por: de Oliveira, Emanuel Almeida Moreira, et al.
Publicado: (2019)

Outcome of Hydroxyurea Use in SCD and Evaluation of Patients’ Perception and Experience in Nigeria
por: Chianumba, Reuben Ikechukwu, et al.
Publicado: (2022)

P-017: POINT-OF-CARE DIAGNOSTIC FOR QUANTIFICATION OF FOETAL HAEMOGLOBIN (HB F) LEVELS IN MONITORING HYDROXYUREA THERAPY FOR CHILDREN WITH SICKLE CELL DISEASE (SCD) IN GHANA
por: C., SEGBEFIA, et al.
Publicado: (2022)

Outcomes of Pregnancy in Sickle Cell Disease Patients: Results from the Prospective ESCORT-HU Cohort Study
por: Habibi, Anoosha, et al.
Publicado: (2023)

Survival and mortality among users and non-users of hydroxyurea with sickle cell disease
por: de Araujo, Olinda Maria Rodrigues, et al.
Publicado: (2015)

ENHANCE—(Electronic Hydroxyurea Adherence): A Protocol to Increase Hydroxyurea Adherence in Patients with Sickle Cell Disease
por: Creary, Susan, et al.
Publicado: (2016)

Emerging Science of Hydroxyurea Therapy for Pediatric Sickle Cell Disease
por: Green, Nancy S., et al.
Publicado: (2013)

Concurrent use of hydroxyurea and deferasirox in Californians with sickle cell disease
por: Wong, Trisha E., et al.
Publicado: (2021)

Mathematical Modeling of Hydroxyurea Therapy in Individuals with Sickle Cell Disease
por: Pandey, Akancha, et al.
Publicado: (2022)

How to implement endurance exercise training in sickle cell disease
por: Messonnier, Laurent A., et al.
Publicado: (2020)

Improving routine outpatient monitoring for patients with sickle-cell disease on hydroxyurea
por: Ward, Joel, et al.
Publicado: (2018)

Optimizing Hydroxyurea Treatment for Sickle Cell Disease Patients: The Pharmacokinetic Approach
por: Nazon, Charlotte, et al.
Publicado: (2019)

A systematic review on hydroxyurea therapy for sickle cell disease in India
por: Pandey, Apoorva, et al.
Publicado: (2022)

The Neonatal Screening Program in Brazil, Focus on Sickle Cell Disease (SCD)
por: Silva-Pinto, Ana C., et al.
Publicado: (2019)

Transition in Sickle Cell Disease (SCD): A German Consensus Recommendation
por: Alashkar, Ferras, et al.
Publicado: (2022)

Drepadom - Home Care Services and Hospitalizations for Sickle Cell Disease Patients during the Covid-19 Pandemic
por: De Luna, Gonzalo, et al.
Publicado: (2020)

Hydroxyurea-Induced miRNA Expression in Sickle Cell Disease Patients in Africa
por: Mnika, Khuthala, et al.
Publicado: (2019)

Effect of Hydroxyurea Treatment on the Inflammatory Markers Among Children With Sickle Cell Disease
por: Zahran, Asmaa M., et al.
Publicado: (2020)

Neutrophils remain detrimentally active in hydroxyurea-treated patients with sickle cell disease
por: Barbu, Emilia Alina, et al.
Publicado: (2019)

Hydroxyurea usage awareness among patients with sickle‐cell disease in Saudi Arabia
por: Alsalman, Mortadah, et al.
Publicado: (2021)

Leveraging mathematical modeling to analyze nonadherence for hydroxyurea therapy in sickle cell disease
por: Pandey, Akancha, et al.
Publicado: (2023)

S269: MALE PATIENTS WITH SCD HAVE A HIGHER RISK OF CEREBROVASCULAR DISEASE, INCREASED INFLAMMATORY MARKERS, AND POORER RESPONSE TO HYDROXYUREA
por: DI Mauro, Margherita, et al.
Publicado: (2023)

Hydroxyurea and sickle cell anemia: effect on quality of life
por: Ballas, Samir K, et al.
Publicado: (2006)

The influence of hydroxyurea on oxidative stress in sickle cell anemia
por: Torres, Lidiane de Souza, et al.
Publicado: (2012)

Candidate Sequence Variants and Fetal Hemoglobin in Children with Sickle Cell Disease Treated with Hydroxyurea
por: Green, Nancy S., et al.
Publicado: (2013)

Hematological differences between patients with different subtypes of sickle cell disease on hydroxyurea treatment
por: Neves, Fabia, et al.
Publicado: (2012)

Patients with sickle cell disease taking hydroxyurea in the Hemocentro Regional de Montes Claros
por: Santos, Fernanda Kelle de Souza, et al.
Publicado: (2011)

Influence of βS-Globin Haplotypes and Hydroxyurea on Arginase I Levels in Sickle Cell Disease
por: Moreira, J. A., et al.
Publicado: (2016)

Hydroxyurea therapy for children with sickle cell disease: describing how caregivers make this decision
por: Creary, Susan, et al.
Publicado: (2015)

A Retrospective Review to Determine If Children with Sickle Cell Disease Receive Hydroxyurea Monitoring
por: Creary, Susan E., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_fobetrpk7q0f7jci6r3ulo4778